Mason Street Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mason Street Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-288,247	Closed	-$26.1M	–	1542
2014 Q4	$26.1M	Buy	288,247 +27,191	+10%	+$2.26M	0.18%	127
2014 Q3	$18.8M	Sell	261,056 -4,256	-2%	-$280K	0.15%	170
2014 Q2	$16.5M	Sell	265,312 -8,261	-3%	-$499K	0.13%	197
2014 Q1	$18.7M	Sell	273,573 -490	-0.2%	-$36.1K	0.15%	183
2013 Q4	$19.3M	Buy	274,063 +97,129	+55%	+$6.6M	0.16%	167
2013 Q3	$12.8M	Buy	176,934 +152,894	+636%	+$10.2M	0.15%	190
2013 Q2	$1.34M	Buy	+24,040	New	+$1.5M	0.01%	817

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Mason Street Advisors's BMRN Position: Q1 2015 in Review

Mason Street Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 288,247 shares — an estimated $26.1M sold.

Mason Street Advisors first reported a position in BMRN in Q2 2013 and held it in 7 quarters. The position peaked at $26.1M in Q4 2014. 378 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

Mason Street Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 288,247 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $26.1M.
Mason Street Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Mason Street Advisors's BioMarin Pharmaceuticals position peaked at $26.1M in Q4 2014.
378 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.